Physician profile

Anil B Kumar

Urology · Rochester Hills, MI

NPI 1073619615

$5,198.42

in general payments reported to CMS, 2019-2025

49 companies · $617 in 2025

The $617 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,127.56

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astellas Pharma US INC $774.18 2019-2024 Myrbetriq, Xtandi
Medtronic, INC. $525.53 2021-2025 Interstim, Altaviva
Sumitomo Pharma America, INC. $455.93 2023-2025 Orgovyx, Gemtesa
Medtronic USA, INC. $346.97 2019-2020
180 Medical, INC. $241.49 2019-2024 Gentlecath
Blue Earth Diagnostics $237.12 2019-2021
Coloplast Corp $192.91 2019-2025
Endo Pharmaceuticals INC. $183.68 2019-2023 Xiaflex
Allergan, INC. $166.46 2019-2021
Tolmar Pharmaceuticals, INC. $161.05 2019-2022
Urogen Pharma, INC. $135.10 2024-2025
Pfizer INC. $133.71 2019-2025
Olympus America INC. $133.26 2021-2025 Itind System
Boston Scientific Corporation $115.97 2021-2025 Spaceoar Vue System - 10ml, Axonics
Axonics, INC. $110.80 2020-2023 Axonics, Bulkamid
Show all 49 companies
CompanyGeneral paymentsYearsTop products
Myovant Sciences INC. $91.94 2022
Merck Sharp & Dohme LLC $78.19 2020-2025 Keytruda
Procept Biorobotics Corporation $76.04 2023-2024 Aquabeam Robotic System, Aquabeam System
Corelink, LLC $75.70 2019
Abbvie INC. $71.90 2022-2024
Nevro Corp. $63.96 2020
Myriad Genetic Laboratories, INC. $59.50 2021-2022
Antares Pharma, INC. $57.73 2023-2025 Xyosted, Nocdurna, Tlando
Janssen Biotech, INC. $53.07 2025 Erleada
Urovant Sciences INC $45.78 2021-2022
Neotract INC. $44.12 2020
Dendreon Pharmaceuticals LLC $41.24 2024 Provenge
Bayer Healthcare Pharmaceuticals INC. $36.75 2019-2022
Halozyme INC $35.22 2023
Isoray, INC $34.82 2021
Verity Pharmaceuticals INC. $34.59 2022-2023 Trelstar
Caldera Medical, INC $33.82 2025
C. R. Bard, INC. & Subsidiaries $33.66 2020
Metuchen Pharmaceuticals $33.63 2019-2020
Dentsply Ih Ab $31.87 2021-2024 Lofric
Cook Medical LLC $24.36 2019-2021
Laborie Medical Technologies Corp. $22.60 2024 Endosheath Technology
Conmed Corporation $22.26 2021
Bioprotect Medical, INC. $22.24 2025 Bioprotect Balloon Implant System
Immunitybio, INC. $21.17 2025
Photocure INC $20.00 2023 Cysview
Teleflex LLC $18.43 2025 Barrigel
Agiliti Surgical, INC. $18.37 2020
Astrazeneca Pharmaceuticals LP $14.86 2025 Lynparza
Medtronic Vascular, INC. $14.42 2019
Alnylam Pharmaceuticals INC. $13.84 2023 Oxlumo
Dentsply Ih INC. $12.90 2021
Acerus Pharmaceuticals Corporation $12.87 2021
Eisai INC. $12.41 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Anil B Kumar

$5,198.42

in general payments reported 2019-2025

Years
2019-2025
Top company
Astellas Pharma US INC
Context
The $617 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).

https://glasscript.com/doctor/275034/anil-b-kumar

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.